Slide 1: Financial Results Quarter Ended December 31, 2015
Financial Results Quarter Ended December 31, 2015
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : Tuesday, Feb 9, 2016 Time : 5:00 pm IST Primary Number: +91 22 3938 1071 Secondary Number: +91 22 6746 8354 6000 1221 Available in – Ahmedabad, Bengaluru, Chennai, Cochin, Delhi, Gurgaon, Hyderabad, Kolkata, Noida. Accessible from all major carriers except BSNL/MTNL. L
Slide 4: Q3'16 Results Analysis
JUBHANT LIFESCIENCES Q3’16 Results Analysis
Slide 5: Income Statement – Q3'FY16
Income Statement – Q3’FY16 Particulars Q3'FY15 Q3'FY16 YoY Growth (Rs Crs) (%) Total Income from Operations 1,445 1,379 -5% Total Expenditure 1,260 1,072 Other Income 6 3 EBITDA including Other Income 191 310 62% Depreciation 80 75 Finance Cost 96 93 Profit after Interest but before Exceptional Item
Slide 6: Financial Highlights – Q3'FY16
Financial Highlights – Q3’FY16 • Income from Operations at Rs. 1,379 Crore, decline of 5% YoY • 12% decline in Life Science Ingredients mainly due to lower input prices from declining crude prices resulting in lower prices of finished products • EBITDA at Rs. 310 Crore, compared to Rs. 191 Crore in
Slide 7: Segmental Revenue Analysis – Q3'FY16
Segmental Revenue Analysis – Q3’FY16 Revenue (Rs. Crs.) Revenue Mix Segmental Revenue Analysis YoY Growth % Q3'FY15 Q3'FY16 (%) Pharmaceuticals 701 728 53% 4% Life Science Ingredients 744 652 47% -12% Income from Operations 1,445 1,379 100% -5% • Pharmaceuticals segment revenue at Rs. 728 Crore, con
Slide 8: Company Revenue – Geography wise – Q3'FY16
Company Revenue – Geography wise – Q3’FY16 Geo-wise Revenue (Rs crs) Q3'FY15 Q3'FY16 Mix % YoY % China and ROW India 413 361 26% -13% 12.1% India International 1,032 1,019 74% -1% 26.2% Europe & USA & Canada 566 572 41% 1% Japan Europe & Japan 283 280 20% -1% 20.3% USA & China and ROW 182 167 12% -9
Slide 9: Pharma Revenue – Geography wise – Q3'FY16
Pharma Revenue – Geography wise – Q3’FY16 Geo-wise Revenue (Rs crs) Q3'FY15 Q3'FY16 Mix % YoY % ROW 9.3% India 39 38 5% -1% India Europe & International 662 689 95% 4% 5.3% Japan USA & Canada 509 522 72% 3% 13.7% Europe & Japan 96 99 14% 4% USA & ROW 57 68 9% 18% Canada 71.8% Income from Operations
Slide 10: Pharma Business Highlights – Q3'FY16
Pharma Business Highlights – Q3’FY16 • Successful inspections of API facility in Nanjangud and CMO and Radiopharmaceuticals facilities in Montreal by the USFDA • Received 5 ANDA approvals during the quarter (Indomethacin ER Capsule 75mg, Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg and 1
Slide 11: LSI Revenue – Geography wise – Q3'FY16
LSI Revenue – Geography wise – Q3’FY16 Geo-wise Revenue (Rs crs) Q3'FY15 Q3'FY16 Mix % YoY % China and India 374 322 49% -14% ROW International 370 329 51% -11% 15.2% Europe, India Europe, North America and Japan 245 230 35% -6% North 49.5% China and ROW 125 99 15% -21% America and Japan Income from
Slide 12: LSI Business Highlights – Q3'FY16
LSI Business Highlights – Q3’FY16 • Strategic initiatives underway for converting some of existing product specific plants to multi- purpose plants to meet enhanced customer demand requirement • Developing new products in Specialty Intermediate plants to increase capacity utilization • Retrofitting
Slide 13: Operating Expenditure Analysis – Q3'FY16
Operating Expenditure Analysis – Q3’FY16 Expenses (Rs Crs) Q3 FY15 % of Sales Q3 FY16 % of Sales YoY Growth % Material Cost 623 43% 482 35% -23% Power & Fuel Cost 99 7% 87 6% -12% Employee Cost 272 19% 283 21% 4% Other Expenses 267 18% 220 16% -17% Total Expenses 1260 87% 1072 78% -15% • Material Co
Slide 14: EBITDA Analysis – Q3'FY16
EBITDA Analysis – Q3’FY16 EBITDA (Rs. Crs) Business Segments Q3'FY15 Q3'FY16 YoY Growth % Pharmaceuticals 140 219 57% Life Science Ingredients 61 101 65% Less: Corp Expenses -10 -10 Reported EBITDA 191 310 62% Margins (%) YoY Variance (Bps) Pharmaceuticals 19.9% 30.1% 1020 Life Science Ingredients 8
Slide 15: Nine Month Results Analysis
Nine Month Results Analysis 14 14
Slide 16: Income Statement – 9M'FY16
Income Statement – 9M’FY16 Particulars 9M'FY15 9M'FY16 YoY Growth (Rs Crs) (%) Total Income from Operations 4,290 4,301 0% Total Expenditure 3,848 3,344 Other Income 37 11 EBITDA including Other Income 478 969 102% Depreciation 222 220 Finance Cost 270 286 Profit after Interest but before Exceptiona
Slide 17: Financial Highlights – 9M'FY16
Financial Highlights – 9M’FY16 • Income from Operations at Rs. 4,301 crs • 12% decline in Life Science Ingredients due to lower input prices from declining crude prices resulting in lower prices of finished products • EBITDA at Rs. 969 crs, compared to Rs. 478 Crore in 9M FY 15 • EBITDA grows 102% Y
Slide 18: Segmental Revenue Analysis – 9M'FY16
Segmental Revenue Analysis – 9M’FY16 Revenue (Rs. Crs.) Revenue Mix Segmental Revenue Analysis YoY Growth % 9M'FY15 9M'FY16 (%) Pharmaceuticals 1,919 2,215 52% 15% Life Science Ingredients 2,370 2,086 48% -12% Income from Operations 4,290 4,301 100% 0% • Income from Operations at Rs. 4,301 crs, • In
Slide 19: Company Revenue – Geography wise – 9M'FY16
Company Revenue – Geography wise- 9M’FY16 Geo-wise Revenue (Rs crs) 9M'FY15 9M'FY16 Mix % YoY % China and India 1,264 1,172 27% -7% ROW, 12% International 3,026 3,129 73% 3% Europe & India, 27% USA & Canada 1,570 1,805 42% 15% Japan, 19% Europe & Japan 883 809 19% -8% China and ROW 573 515 12% -10%
Slide 20: Pharma Revenue – Geography wise – 9M'FY16
Pharma Revenue – Geography wise- 9M’FY16 Geo-wise Revenue (Rs crs) 9M'FY15 9M'FY16 Mix % YoY % ROW, 8.0% India 97 111 5% 14% India, 5.0% International 1,822 2,104 95% 15% Europe & USA & Canada 1,385 1,663 75% 20% Japan, 11.9% Europe & Japan 282 264 12% -6% USA & ROW 155 177 8% 14% Canada, 75.1% Inco
Slide 21: Pharma Business Highlights – 9M'FY16
Pharma Business Highlights – 9M’FY16 • All facilities have been inspected successfully by the USFDA during the year • 38 commercial APIs, including 24 in North America, 23 in Europe and 28 in ROW • 51 commercial Solid Dosage Formulations products, including 31 in North America, 29 in Europe and 27 i
Slide 22: LSI Revenue – Geography wise – 9M'FY16
LSI Revenue – Geography wise- 9M’FY16 Geo-wise Revenue (Rs crs) 9M'FY15 9M'FY16 Mix % YoY % China and India 1,167 1,061 51% -9% ROW, 16.2% International 1,204 1,025 49% -15% India, Europe, North America Europe, 50.9% 785 687 33% -13% North and Japan America and China and ROW 418 338 16% -19% Japan,
Slide 23: LSI Business Highlights – 9M'FY16
LSI Business Highlights – 9M’FY16 • Volume reduction in Pyridine due to lower demand from global agrochemical customers • Better price realization in Nutritional Products • Lower revenue in Life Science Chemicals due to lower demand from global agrochemical customers • Better performance in Fine Ing
Slide 24: Operating Expenditure Analysis – 9M'FY16
Operating Expenditure Analysis – 9M’FY16 Expenses (Rs Crs) 9M'FY15 % of Sales 9M'FY16 % of Sales YoY Growth % Material Cost 1948 45% 1549 36% -20% Power & Fuel Cost 298 7% 288 7% -3% Employee Cost 815 19% 843 20% 3% Other Expenses 787 18% 664 15% -16% Total Expenses 3848 90% 3344 78% -13% • Material
Slide 25: EBITDA Analysis 9M'FY16
EBITDA Analysis 9M’FY16 EBITDA (Rs. Crs) Business Segments 9M'FY15 9M'FY16 YoY Growth % Pharmaceuticals 245 660 170% Life Science Ingredients 256 341 33% Less: Corp Expenses -22 -32 Reported EBITDA 478 969 102% EBITDA Margins (%) YoY Variance (Bps) Pharmaceuticals 12.7% 29.8% 1704 Life Science Ingre
Slide 26: Debt Profile
Debt Profile Particulars 31-Mar-15 30-Sep-15 31-Dec-15 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Standalone 105 80 65 Subsidiaries 338 338 347 Total 443 417 412 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 1,513 1,421 1,263 Subsidiaries 509 552 542 Total 2,022 1,973 1,805 Gross Debt 4,790
Slide 27: Outlook
Outlook Going forward, expect to continue the growth momentum of the company • Revenue growth in Pharmaceuticals segment expected to be driven by: • New product launches in Generics and Radiopharmaceuticals • Increased utilization in CMO of Sterile Injectables • Life Science Ingredients to deliver
Slide 28: For more information
For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91-120-436 1002 Ph: +91-22-6645 1209 E-mail: ravi_agrawal@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Kanika Mittal Jubilant Life Sciences Limited Perfect Relati